bioMérieux (OTCMKTS:BMXMF - Get Free Report) was downgraded by investment analysts at Royal Bank of Canada from a "moderate buy" rating to a "hold" rating in a research note issued on Wednesday,Zacks.com reports.
bioMérieux Price Performance
BMXMF remained flat at $128.95 during trading hours on Wednesday. bioMérieux has a 12 month low of $93.50 and a 12 month high of $134.38. The company has a debt-to-equity ratio of 0.10, a current ratio of 2.21 and a quick ratio of 1.20. The business's 50 day simple moving average is $126.78 and its two-hundred day simple moving average is $116.31.
About bioMérieux
(
Get Free Report)
bioMérieux SA develops and produces in vitro diagnostic solutions for the diagnosis of infectious diseases in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers systems that use biological samples, such as blood, saliva, urine, etc. for the diagnosis of infectious diseases, including bacterial infections, parasitic infections, and viral infections; and microbiological control of production or the production environment primarily for food, pharmaceutical, and cosmetic industries.
Read More
Before you consider bioMérieux, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and bioMérieux wasn't on the list.
While bioMérieux currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
